SNDA trades 3.4% below Wall Street's consensus target of $42.33.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SNDA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Sonida Senior Living, Inc. (SNDA) has a Wall Street consensus price target of $42.33, based on estimates from 5 covering analysts. With the stock currently trading at $40.93, this represents a potential upside of +3.4%. The company has a market capitalization of $819M.
Analyst price targets range from a low of $37.00 to a high of $48.00, representing a 26% spread in expectations. The median target of $42.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, SNDA trades at a trailing P/E of -9.7x. Analysts expect EPS to grow +32.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ENSGThe Ensign Group, Inc. | $10.0B | $170.87 | $222.33 | +30.1% | Buy | 22.6x | 13 |
BKDBrookdale Senior Living Inc. | $3.7B | $15.42 | $18.75 | +21.6% | Buy | — | 12 |
SGRYSurgery Partners, Inc. | $2.2B | $17.17 | $19.33 | +12.6% | Buy | 40.0x | 22 |
CTRECareTrust REIT, Inc. | $9.9B | $41.80 | $44.25 | +5.9% | Buy | 27.9x | 19 |
SHCSotera Health Company | $5.1B | $18.02 | $21.00 | +16.5% | Buy | 18.6x | 12 |
NHCNational HealthCare Corporation | $3.4B | $216.40 | — | — | — | 27.2x | — |
ADUSAddus HomeCare Corporation | $2.0B | $105.97 | $122.00 | +15.1% | Buy | 15.2x | 16 |
WELLWelltower Inc. | $166.5B | $237.59 | $237.80 | +0.1% | Buy | 82.0x | 35 |
VTRVentas, Inc. | $44.7B | $94.07 | $95.86 | +1.9% | Buy | 150.8x | 32 |
OHIOmega Healthcare Investors, Inc. | $14.8B | $49.62 | $50.43 | +1.6% | Hold | 25.0x | 28 |
Quick answers to the most common questions about buying SNDA stock.
The consensus price target for SNDA is $42.33, close to the current price of $40.93 (3.4% implied move). Based on 5 analyst estimates, the stock appears fairly valued near current levels.
SNDA has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is mixed, with 2 Hold ratings making up the largest segment. The consensus 12-month price target of $42.33 implies 3.4% upside from current levels.
SNDA's current price is $40.93 with a consensus target of $42.33 (3.4% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $48 for SNDA, while the most conservative target is $37. The consensus of $42.33 represents the median expectation. These targets typically reflect 12-month expectations.
SNDA is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 2 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SNDA stock forecast based on 5 Wall Street analysts shows a consensus price target of $42.33, with estimates ranging from $37 (bear case) to $48 (bull case). The median consensus rating is "Buy".
SNDA appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $42.33 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SNDA analyst price targets range from $37 to $48, a 26% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $42.33 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.